Bright Minds Biosciences Stock Last Dividend Paid
| DRUG Stock | USD 39.18 1.07 2.81% |
Bright Minds Biosciences fundamentals help investors to digest information that contributes to Bright Minds' financial success or failures. It also enables traders to predict the movement of Bright Stock. The fundamental analysis module provides a way to measure Bright Minds' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bright Minds stock.
Bright | Last Dividend Paid |
Bright Minds Biosciences Company Last Dividend Paid Analysis
Bright Minds' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Bright Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Bright Minds is extremely important. It helps to project a fair market value of Bright Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Bright Minds' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bright Minds' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bright Minds' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Bright Minds Biosciences has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
| All Next | Launch Module |
Bright Minds ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.Environmental | Governance | Social |
Bright Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 263.86 M | ||||
| Shares Outstanding | 6.08 M | ||||
| Shares Owned By Insiders | 27.28 % | ||||
| Shares Owned By Institutions | 44.27 % | ||||
| Number Of Shares Shorted | 264.76 K | ||||
| Price To Book | 62.97 X | ||||
| EBITDA | (7.28 M) | ||||
| Net Income | (7.37 M) | ||||
| Cash And Equivalents | 8.64 M | ||||
| Cash Per Share | 0.71 X | ||||
| Total Debt | 73.55 K | ||||
| Current Ratio | 22.88 X | ||||
| Book Value Per Share | 1.37 X | ||||
| Cash Flow From Operations | (7.02 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (0.63) X | ||||
| Target Price | 4.87 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 268.26 M | ||||
| Total Asset | 6.88 M | ||||
| Retained Earnings | (31.55 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 6.88 M |
About Bright Minds Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Bright Minds Piotroski F Score and Bright Minds Altman Z Score analysis. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.